Project Grant F32HL186764
Award Date 1/7/27
Completion Date 1/6/28
Dollars Obligated $185K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $330,176 on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentored research on the effect of severe obesity on regional lung perfusion in acute hypoxemic respiratory failure. The award funds two primary research aims. Aim 1 defines the association between severe obesity and regional lung perfusion in a novel...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $391,700 under the Cardiovascular Diseases Research program (CFDA 93.837) on February 15, 2026. The award funds mixed-methods health services research to optimize the regionalization of care for acute type A aortic dissection (ATAAD) and increase appropriate interfacility transfer of ATAAD patients from low-volume to high-volume aortic centers. The research...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $539,066 to Massachusetts General Hospital (The General Hospital Corporation, Research Management Division) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating the role of microglial extracellular vesicles in the progression of atherosclerosis following traumatic brain injury. The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $247,500 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025 through August 31, 2027. The award supports research to develop a non-invasive biomarker-based classifier model for early detection of pulmonary vascular dysfunction (PVD) in acute respiratory distress syndrome (ARDS) patients. ARDS patients with PVD...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1,579,554 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 10, 2025, to conduct multi-trait, multi-ancestry, and multi-omic genetic studies of chronic obstructive pulmonary disease (COPD) and asthma using data integrated across global biobanks. The work integrates genetic and phenotypic data from the All of Us Research Program,...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $197,634 in project grant funding on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This K23 mentored research award funds investigation of inhaled nitric oxide (INO) responder and non-responder phenotypes in persistent pulmonary hypertension of the newborn (PPHN) using electrical impedance tomography (EIT)...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 1, 2026, for whole genome sequence interpretation to identify new genes and mechanisms underlying coronary artery disease and familial hypercholesterolemia. The award funds research to improve genetic diagnostic yield for familial hypercholesterolemia, an inherited form of...